ARO C3
Alternative Names: ARO-C3Latest Information Update: 28 Sep 2025
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Complement C3 inhibitors; RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II IgA nephropathy; Membranoproliferative glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
- No development reported Liver disorders
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Liver-disorders in USA
- 10 Mar 2025 Interim pharmacodynamics and adverse events data from a phase I/II trial in IgA nephropathy released by Arrowhead Pharmaceuticals
- 28 Feb 2023 Interim pharmacodynamics and adverse events data from a phase I/II trial in Paroxysmal nocturnal hemoglobinuria, Membranoproliferative glomerulonephritis and IgA nephropathy released by Arrowhead Pharmaceuticals